Patents by Inventor Hemanshu Mundhada
Hemanshu Mundhada has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11407976Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: GrantFiled: October 6, 2020Date of Patent: August 9, 2022Assignee: CysBio ApSInventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Publication number: 20210095245Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: ApplicationFiled: October 6, 2020Publication date: April 1, 2021Inventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Patent number: 10822627Abstract: The present invention relates to a hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1. The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.Type: GrantFiled: April 13, 2018Date of Patent: November 3, 2020Assignee: Evonik Operations GmbHInventors: Steffen Osswald, Heiko Schuster, Jurgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter
-
Patent number: 10793826Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: GrantFiled: January 27, 2016Date of Patent: October 6, 2020Assignee: CysBio ApsInventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Patent number: 10513682Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: GrantFiled: January 27, 2016Date of Patent: December 24, 2019Assignee: CYSBIO APSInventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Publication number: 20190367930Abstract: The present invention generally relates to industrial microbiology, and specifically to the production of biochemical compounds, such as L-serine, L-tyrosine, mevalonate and their derivatives, and recombinant polypeptides using genetically modified microorganisms. More particularly, the present invention pertains to the decoupling of cell growth from production of biochemical compounds, such as L-serine, L-tyrosine, mevalonate and their derivatives, in a microorganism by down regulating the nucleotide biosynthesis in said microorganism.Type: ApplicationFiled: July 28, 2017Publication date: December 5, 2019Inventors: Songyuan Li, Christian Bille Jendresen, Lasse Ebdrup Pedersen, Jenny Landberg, Kristoffer Bach Falkenberg, Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Publication number: 20180237814Abstract: The present invention relates to it hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1. The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.Type: ApplicationFiled: April 13, 2018Publication date: August 23, 2018Inventors: Steffen Osswald, Heiko Schuster, Jurgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter
-
Patent number: 9957536Abstract: The present invention relates to a hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1, The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.Type: GrantFiled: November 16, 2012Date of Patent: May 1, 2018Assignee: Evonik Technochemie GmbHInventors: Steffen Osswald, Heiko Schuster, Jurgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter
-
Patent number: 9926536Abstract: Novel glucose oxidase (GOx) variants are disclosed that have the substitutions of T30V and I94V set forth in SEQ ID NO:1, and additionally at least one further amino acid substitution in the enzyme sequence in any of the positions S53; A137; A173; A332; F414 and V560. The GOx variants herein exhibit specificity for glucose and significantly reduced oxygen consumption rates and/or increased enzyme activity for electron mediators other than oxygen. Also provided are assay devices incorporating at least one of the GOx variants herein for improved blood glucose measurements.Type: GrantFiled: July 27, 2015Date of Patent: March 27, 2018Assignee: Roche Diabetes Care, Inc.Inventors: Marco Bocola, Hartmut Duefel, Erik Uwe Arango Gutierrez, Dieter Heindl, Thomas Meier, Hemanshu Mundhada, Ulrich Schwaneberg, Michael Tacke
-
Publication number: 20180016546Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: ApplicationFiled: January 27, 2016Publication date: January 18, 2018Inventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Publication number: 20180010157Abstract: The present invention generally relates to the microbiological industry, and specifically to the production of L-serine or L-serine derivatives using genetically modified bacteria. The present invention provides genetically modified microorganisms, such as bacteria, wherein the expression of genes encoding for enzymes involved in the degradation of L-serine is attenuated, such as by inactivation, which makes them particularly suitable for the production of L-serine at higher yield. The present invention also provides means by which the microorganism, and more particularly a bacterium, can be made tolerant towards higher concentrations of serine. The present invention also provides methods for the production of L-serine or L-serine derivative using such genetically modified microorganisms.Type: ApplicationFiled: January 27, 2016Publication date: January 11, 2018Applicant: Danmarks Tekniske UniversitetInventors: Hemanshu Mundhada, Alex Toftgaard Nielsen
-
Publication number: 20160002609Abstract: Novel glucose oxidase variants are disclosed that have besides the two substitutions T30V and I94V according to SEQ ID NO:1, additionally at least one further amino acid substitution in the polypeptide sequence in any of the positions S53; A137; A173; A332; F414 and V560. The glucose oxidase variants herein exhibit specificity for glucose and significantly reduced oxygen consumption rates and/or increased enzyme activity for electron mediators other than oxygen. Also provided are assay devices incorporating at least one of the GOx variants herein for improved blood glucose measurements.Type: ApplicationFiled: July 27, 2015Publication date: January 7, 2016Applicant: ROCHE DIABETES CARE, INC.Inventors: Marco Bocola, Hartmut Duefel, Erik Uwe Gutierrez, Dieter Heindl, Thomas Meier, Hemanshu Mundhada, Ulrich Schwaneberg, Michael Tacke
-
Publication number: 20150056667Abstract: The present invention relates to a hydantoinase having an amino acid sequence selected from (i) or (ii), with (i) amino acid sequence selected from SEQ ID NO: 6-20 and SEQ ID NO: 73-119 (ii) amino acid sequence wherein in the amino acid sequence of SEQ ID NO: 6-20 and SEQ ID NO: 73-119, 1 to 75 amino acid residues have been substituted, deleted, inserted and/or added, and wherein further the catalytic activity of the hydantoinase is higher by a factor of at least 1.2 than the catalytic activity of the hydantoinase having amino acid sequence SEQ ID NO: 1, The present invention further relates to a process for preparing amino acids, wherein said hydantoinase is used.Type: ApplicationFiled: November 16, 2012Publication date: February 26, 2015Inventors: Steffen Osswald, Heiko Schuster, Jürgen Roos, Andreas Karau, Ulrich Schwaneberg, Ronny Martinez, Hemanshu Mundhada, Ursula Holter